MARATTO

article · World Journal of Gastroenterology

Optimized sequential therapy <i>vs</i> 10- and 14-d concomitant therapy for eradicating <i>Helicobacter pylori</i>: A randomized clinical trial

20244 citationsOpen accessMohammed V University

Abstract

The optimized 14-d sequential therapy is a safe and effective alternative. Its eradication rate is comparable to that of the 14-d concomitant therapy while causing fewer AEs and allowing a gain in terms of cost.

Research topics

  • Helicobacter pylori-related gastroenterology studies
  • Gastroesophageal reflux and treatments
  • Veterinary medicine and infectious diseases

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.3748/wjg.v30.i6.556

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.